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Purpose: The expression of natriuretic peptides in the neural bundles of the anterior portion of the optic 
nerves and their functions in regulating vessel tone and blood flow may suggest a possible role in the 
pathogenesis of glaucoma. The purpose of this study was to investigate the association between 
normal-tension glaucoma and the genetic variations of atrial natriuretic peptide (Nppa) and natriuretic peptide 
receptor A (Npr1) gene.
Methods: Sixty-seven Korean normal-tension glaucoma (NTG) patients and 100 healthy subjects (as normal 
controls) were enrolled. DNA from peripheral blood leukocytes was extracted, and the genotypes of five 
polymorphisms (c.94G>A, c.454T>C, IVS1+16C>T, IVS2+701G>A, and c.-764C>G) in the Nppa gene and 
one polymorphism (c.1023G>C) in the Npr1 gene were determined using the restriction fragment length 
polymorphism and the SNaPshot methods. The genotype and allele frequencies of these polymorphisms in 
patients with NTG and normal controls were compared using the Fisher's exact test and the chi-square test.
Results: In both groups, the genotype distributions were in accordance with the Hardy-Weinberg equilibrium. 
There was no significant difference in the frequency of the Nppa and Npr1 alleles or genotypes in the 
normal-tension glaucoma group as compared to the control group.
Conclusions:  Nppa and Npr1 gene polymorphisms are not associated with normal-tension glaucoma, 
suggesting that this gene does not have an important role in the pathogenesis of optic neuropathy in this 
disease.
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Glaucoma is a degenerative optic neuropathy characterized 
by optic nerve head changes and visual field loss, often 
related to raised intraocular pressure (IOP). Factors other than 
IOP are likely to have a role in the pathogenesis of 
glaucomatous optic neuropathy, particularly in individuals 
with normal-tension glaucoma (NTG). NTG is an entity 
of progressive glaucomatous optic neuropathy and 
corresponding visual field defects with IOP in the statistically 
normal range. Because of the normal IOP, other factors such 
as vascular dysregulation are supposed to play an important 
role in the pathogenesis of NTG. Since up to 21% of NTG 
patients were reported to have a family history, it is 
suggested that these patients may be genetically predisposed 
to developing NTG.
1
The natriuretic peptide (NP) family is composed of atrial 
natriuretic peptide (ANP), brain natriuretic peptide (BNP), 
and C-type natriuretic peptide (CNP).
2-4 ANP and BNP are 
circulating peptides mainly produced in the heart that are 
involved in the regulation of natriuresis, diuresis, and blood 
flow.
3,5 CNP predominantly acts as a vasodilator and is found 
principally in the central nervous system and endothelial 
cells.
4,6 Three mammalian members of the natriuretic peptide 
gene family have been identified: Nppa, Nppb, and Nppc, 
which encode ANP, BNP, and CNP, respectively. The 
Nppa gene is located in 1p36.2 and contains three exons 
(Fig. 1A).Kor J Ophthalmol Vol.21, No.1, 2007
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Fig. 1. Genomic structures. (A) Nppa gene; (B) Npr1 gene (provided in the public domain by the National Center for Biotechnology
Information, Bethesda, MD, U. S. A.; available at http://www.ncbi.nlm.nih.gov).
Three NP receptors -natriuretic peptide receptor A (NPRA), 
natriuretic peptide receptor B (NPRB) and natriuretic peptide 
receptor C (NPRC)- have been identified in mammalian 
tissue. NPRA and NPRB are linked to the cGMP-dependent 
signaling cascade and mediate many of the cardiovascular 
and renal effects of NPs. NPRA is activated by ANP and, 
to a lesser extent, BNP. NPRC plays a role in the clearance 
of the peptides, and it has been reported that NPs act to 
inhibit cardiomyocytes, vascular endothelial cells, and/or 
astrocyte proliferation in part through this receptor.
7-10 The 
chromosomal locations of the genes encoding these three 
receptor subtypes are designated as Npr1, Npr2, and Npr3, 
corresponding to NPRA, NPRB, and NPRC, respectively. 
The primary structure of the Npr1 gene is located on 
1q21-q22 and contains 22 exons interrupted by 21 introns 
(Fig. 1B).
NPs have been shown to inhibit vascular cell growth and 
regulate vessel tone, and may play an important modulatory 
role in angiogenesis.
9,11 Rollin et al
12 reported the expression 
of NPs in neural retinal, glial, and vascular elements in the 
normal adult retina, and also in the neural bundles of the 
anterior portion of optic nerves. This may present a role for 
these peptides in maintaining both the neural and vascular 
integrity of the mature retina and optic nerve. Collectively, 
these results may suggest that the NP system might be 
involved in the development of glaucoma.
In this study, we investigated the association between NTG 
and the single nucleotide polymorphisms in atrial natriuretic 
peptide and natriuretic peptide receptor A genes.
Materials and Methods
Subjects
The study population consisted of 67 patients with NTG 
and 100 healthy volunteers. All subjects were of Korean 
heritage and were apparently unrelated. NTG patients were 
recruited from the Glaucoma Clinic and volunteers from the 
Health Promotion Clinic of Seoul National University 
Hospital. Human subject participation and receipt of informed 
consent from each subject were approved by the Institutional 
Review Board of Seoul National University Hospital Clinical 
Research Institute.
The diagnostic criteria for NTG included normal 
intraocular pressure (IOP), glaucomatous optic disc cupping, 
glaucomatous visual field defects, an open anterior chamber 
angle, and the absence of any contributing ocular or systemic 
disorders. IOP was measured using a Goldmann applanation 
tonometer. Normal IOP was defined as a diurnal IOP 
persistently below 21 mmHg without medication. Visual 
fields of NTG patients were evaluated using the 30-2 
program of the Humphrey Visual Field Analyzer Model 750 
(Zeiss Inc., San Leandro, CA, U. S. A.) or Model 630 
(Allergan Inc., San Leandro, CA, U. S. A.). Reliable fields 
were those with a fixation loss rate of ≤20% and 
false-positive and false-negative error rates of ≤20%. A 
glaucomatous visual field defect was defined as a Glaucoma 
Hemifield test outside normal limits on at least two fields, 
or a cluster of three or more non-edge points in a location 
typical for glaucoma (all of which are depressed on the 
pattern deviation plot at a P < 5% level, and one of which 
is depressed at a P < 1% level on two consecutive fields), 
or a corrected pattern standard deviation that occurs in less 
than 5% of normal fields.
Healthy volunteers who had completed medical and 
ophthalmological examinations at the Health Promotion 
Clinic served as controls. They had best corrected visual 
acuity of 20/25 and IOP of 21 mmHg or less. Subjects with 
any suspicious findings of glaucoma in the disc and fundus 
(e.g., cup:disc ratio of more than 0.6, notch in the neural rim, 
vertically oval cup, zone beta peripapillary atrophy, retinal 
nerve fiber layer defect, choroidal sclerosis, or abnormalities JW Jeoung, et al. NORMAL-TENSION GLAUCOMA AND NATRIURETIC PEPTIDE 
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Gene Polymorphism Location Primer sequences (5' to 3') PCR product size 
(bp) PCR Tm* (℃)
c.94G>A Exon 1 F ACCGTGAGCTTCCTCCTTTT
R GGAGTGAGCACAGCATCAGA 164 55
Nppa
 gene c.454T>C Exon 3 F GGCACACTCATACATGAAGCTGACTTTT
R GCAGTCTGTCCCTAGGCCCA 133 55
IVS1+16C>T Intron 1 F AGACAGAGCAGCAAGCAGTG
R CATTTCCATCCCCAGTTCC 640 55
IVS2+701G>A Intron 2 F GGGAGGCCAAGGCGGGTGGATCAC
R CCCCACCCCAGCCTGATGACCCTCTG 445 63
c.-764C>G Promoter
region
F AAATTGGCTGCGTCCTCTAA
R TGATGAAGCTCCCAGGAATC 152 55
Npr1
 gene 1023G>C Exon 3 F ACACCTGGCCTATGAGCAGT
R CCAGTGTCCTCCTCCATCAT 199 55
* PCR annealing temperature.
Table 1. Primer sequences, polymerase chain reaction (PCR) product sizes, and PCR annealing temperatures
of the disc vessels) were not included. The two groups were 
compared with respect to average age, gender ratio, and IOP.
Gene polymorphisms
Six polymorphisms were identified through the review of 
articles. The exon 1 (c.94G>A), the exon 3 (c.454T>C), the 
intron 1 (IVS1+16C>T), the intron 2 (IVS2+701G>A) and 
the promoter region (c.-764C>G) polymorphisms in the Nppa 
gene, and the exon 3 (c.1023G>C) polymorphism in the Npr1 
gene were selected and analyzed. Gene symbols and 
sequence variations are described according to the 
recommendations of the HUGO Gene Nomenclature 
Committee.
13 The Nppa and Npr1 reference sequences are 
NCBI accession no. NC_000001.9 (http://www.ncbi.nlm.nih.gov; 
provided in the public domain by the National Center for 
Biotechnology Information, Bethesda, MD, U. S. A.).
The c.94G>A polymorphism was analyzed using the 
SNaPshot technique, and others were identified using 
restriction fragment length polymorphism with polymerase 
chain reaction (PCR). The primers used in this study are 
demonstrated in Table 1.
Genetic Analysis and Genotype Identification: PCR- 
RFLP reaction
Peripheral blood samples of NTG patients and controls 
were collected from the antecubital vein and stored in an 
EDTA tube for less than one day. Genomic DNA extraction 
was performed using a Gentra PureGene DNA isolation kit 
(Gentra System Inc., Minneapolis, MN, U. S. A.). PCR of 
the extracted DNA samples was performed on a final volume 
of 20 µL, which contained 50 ng of genomic DNA, 10 mM 
Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.01% 
gelatin, 200 µM of each dNTP, 8 pmole of each primer and 
0.5 U of Taq polymerase (AmpliTaq Gold
TM, Applied 
Biosystems, Foster City, CA, U. S. A.). The PCR conditions 
used were 95°C for the initial 10 minutes, and 35 cycles of 
95°C for 30 seconds, each annealing temperature (Tm) for 
30 seconds and 72°C for 1 minute, and a final extension at 
72°C for 7 minutes. The annealing temperature of each 
primer for the PCR reaction is demonstrated in Table 1.
The PCR products obtained were then digested with 
restriction enzymes: ScaI for c.454T>C digestion yielded 77 
and 56 bp fragments for the T allele and a 133 bp fragment 
for the C allele; BsxXI for IVS1+16C>T digestion yielded 
442 and 198 bp fragments for the C allele and 262, 198, and 
180 bp fragments for the T allele. MspI for IVS2+701G>A 
yielded 278, 136, and 31 bp fragments for the G allele and 
309 and 136 bp fragments for the A allele, and BslI for 
c.-764C>G digestion yielded a 152 bp fragment for the C 
allele and 110 and 42 bp fragments for the G allele. TaqI 
for c.1023G>C of Npr1 gene yielded a 199 bp fragment for 
the G allele and 166 and 33 bp fragments for the C allele. 
The genotypes were identified after electrophoresis of the 
final digestion product in 2% agarose gel.
Genetic Analysis and Genotype Identification: SNaP shot 
reaction
As described previously, the c.94G>A polymorphism was 
analyzed using the SNaPshot technique with the automatic 
genetic analyzer (Applied Biosystems, Foster City, CA, U. S. 
A.). This method relies on the extension of a primer that ends 
one base short of a polymorphic site, with fluorescent labeled 
dideoxy nucleotides, which are complementarily incorporated 
according to the sequence of the amplified target. The 
SNaPshot mixtures consisted of 5 uL of SNaPshot Multiplex 
Ready Reaction reagent (Applied Biosystems, Foster City, 
CA, U. S. A.), 5 pmol of SNaPshot primer (5'- 
CTAATCCCATGTACAATGCC-3'), and 3 uL of purified 
PCR product. The reaction was performed as follows: 25 
cycles at 96°C for 10 seconds, 50°C for five seconds, and 
60°C for 30 seconds. After extension, the samples were 
treated with shrimp alkaline phosphatase. The samples were 
electrophoresed on an automated ABI PRISM 3100 genetic Kor J Ophthalmol Vol.21, No.1, 2007
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Patients (n=67) Controls (n=100) P value
Age (years) 48.8±10.2 49.3±9.2 NS
*
Gender ratio (M:F) 28:39 47:53  NS
†
IOP (mmHg) 16.0±2.4
§ 15.3±2.5 NS
*
Max IOP 17.3±2.4
Min IOP 14.5±2.8
Family history of Glaucoma 14 (20.3%) 0 (0%) 0.001
‡
Visual field
  MD (dB) -6.63±5.50
  PSD (dB)  8.43±5.00
NS: not significant, IOP: intraocular pressure, MD: mean deviation of program 30-2 of Humphrey Visual Field 
Analyzer, PSD: pattern standard deviation of program 30-2 of Humphrey Visual Field Analyzer.
* Independent t-test,
 † Chi-square test,
 ‡ Fisher's exact test, § Mean of diurnal IOPs.
Table 2. Characteristics of normal-tension glaucoma patients and controls
analyzer and analyzed with ABI GeneScan 3.1 analysis 
software (Applied Biosystems). Size determinations were 
performed using the GeneScan-120 LIZ size calibrator with 
Genotyper Version 2 data collection software.
Statistical Analysis
The frequencies of the genotypes and alleles of the 
polymorphisms were compared between NTG patients and 
the controls. The results were taken to be statistically 
significant when the p value was <0.05. For the Fisher's exact 
test, double-sided p-values were calculated using the sum of 
small p-values.
14 The statistical analyses were performed 
using SPSS for Windows version 10.0 (SPSS Inc., Chicago, 
IL, U. S. A.). Conformance with the Hardy-Weinberg 
equilibrium for the genotype distributions was determined 
using the chi-square test for the goodness of fit.
Results
The characteristics of the NTG patients and the controls 
are presented in Table 2. No significant differences were 
found between the two groups in terms of age, gender ratio, 
and IOP. The family history of glaucoma was found in 14 
NTG patients (20.3%). The mean deviation scores from 
program 30-2 of the Humphrey visual field analyzer implied 
moderate visual field defects in patients with NTG.
The genotype and allele frequencies of the polymorphisms 
in NTG patients (n=67) and controls (n=100) are shown in 
Table 3. In both groups, the genotype distributions were in 
accordance with the Hardy-Weinberg equilibrium. There 
was no significant difference in the frequency of the 
polymorphisms of Nppa and Npr1 gene alleles or genotypes 
between the NTG group and the control group. In the 
subgroup analysis of the age at diagnosis, there was no 
significant association between the Nppa and Npr1 genotype 
and NTG patients.
Discussion
IOP is recognized as the only factor among multiple others 
responsible for optic nerve damage in glaucoma. But 
considerable evidence has been collected implicating vascular 
insufficiency as the cause of glaucomatous nerve fiber 
damage.
15-18 The expression of NPs in the neural bundles of 
the anterior portion of optic nerves
12 and their functions in 
regulating vessel tone and blood flow
9 may suggest a possible 
role in the pathogenesis of glaucoma. This study investigated 
the association between NTG and the genetic variations of 
the Nppa and Npr1 gene.
NPs are potent vasodilators that may play a role in the 
pathogenesis of various vascular diseases such as 
hypertension. It has been suggested that NPs and their 
receptors in the human retina have a paracrine or autocrine 
function.
12 NPs could also act as neurotransmitters or 
neuromodulators in the retina, as do other peptides such as 
vasoactive intestinal peptide or neuropeptide Y, which have 
effects similar to those of ANP.
19,20 Interestingly, it has been 
suggested that ANP may contribute to cortical spreading 
depression-induced neuroprotection in the rat cerebral cortex, 
via effects on c-GMP production and other signal- 
transduction pathways.
21
The c.454T>C polymorphism in exon 3 of the Nppa gene 
was previously known as the ScaI Nppa gene polymorphism 
because it can be detected by using ScaI restriction enzymes. 
It has been reported that this polymorphism has a significant 
association with nonfatal myocardial infarction, multiple 
-vessel coronary artery disease, hypertension, and 
microalbuminuria.
22-29 Allele frequencies of the Nppa gene 
polymorphism have been reported to vary among ethnic 
groups. The frequency of the C allele is known to be 26.0% 
(n=50) in French Caucasians and 57.6% (n=48) in black 
Africans.
30 In healthy subjects, the frequency of the C allele 
in Koreans is known to be 1.0% (n=180).
31 In our study, its 
frequency was 1.5% (n=67) in NTG patients and 0.0% JW Jeoung, et al. NORMAL-TENSION GLAUCOMA AND NATRIURETIC PEPTIDE 
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Genotypes/Alleles NTG Patients (N=67) Controls (N=100) P  value Remark
Nppa gene
c.94G>A
GG 53 (79.1%) 83 (83.0%) 0.525
* GG vs. GA+AA
GA 13 (19.4%) 16 (16.0%)
AA 1 (1.5%) 1 (1.0%) 0.483
† GG+GA vs. AA
G 119 (88.8%) 182 (91.0%) 0.510
* G vs. A
A 15 (11.2%) 18 (9.0%)
c.454T>C
TT 66 (98.5%) 100 (100.0%) 0.401
† TT vs. TC+CC
TC 1 (1.5%) 0 (0.0%)
CC 0 (0.0%) 0 (0.0%) 1
† TT+TC vs. CC
T 133 (99.3%) 200 (100.0%) 0.221
† T vs. C
C 1 (0.7%) 0 (0.0%)
IVS1+16C>T
CC 67 (100.0%) 100 (100.0%) 1
† CC vs. CT+TT
CT 0 (0.0%) 0 (0.0%)
TT 0 (0.0%) 0 (0.0%) 1
† CC+CT vs. TT
C 134 (100.0%) 200 (100.0%) 1
† C vs. T
T 0 (0.0%) 0 (0.0%)
IVS2+701G>
A
GG 54 (80.6%) 82 (82.0%) 0.820
* GG vs. GA+AA
GA 12 (17.9%) 16 (16.0%)
AA 1 (1.5%) 2 (2.0%) 0.647
† GG+GA vs. AA
G 120 (89.6%) 180 (90.0%) 0.893
* G vs. A
A 14 (10.4%) 20 (10.0%)
c.-764C>G
CC 65 (97.0%) 97 (97.0%) 0.683
† CC vs. CG+GG
CG 2 (3.0%) 3 (3.0%)
GG 0 (0.0%) 0 (0.0%) 1
† CC+CG vs. G
C 132 (98.5%) 197 (98.5%) 1
† C vs. G
G 2 (1.5%) 3 (1.5%)
Npr1 gene c.1023G>C
GG 46 (68.7%) 79 (79.0%) 0.131
* GG vs. GC+CC
GC 21 (31.3%) 20 (20.0%)
CC 0 (0.0%) 1 (1.0%) 0.599
† GG+GC vs. CC
G 113 (84.3%) 178 (89.0%) 0.212
* G vs. C
C 21 (15.7%) 22 (11.0%)
NTG: normal-tension glaucoma.
* Chi-square test, 
†Fisher's exact test.
Table 3. Genotype and allele frequencies
(n=100) in controls. The extremely low prevalence of Nppa 
polymorphism in our NTG and control subjects suggests this 
factor does not have a significant role in the pathogenesis of 
NTG.
IVS1+16C>T, IVS2+701G>A, c.-764C>G, and c.94G>A 
polymorphisms in the Nppa gene were reported to have 
significant associations with microalbuminuria, stroke, and 
hypertension.
29,32,33 And the c.1023G>C mutation of the Npr1 
gene-which is the missense mutation of methionine (ATG) to 
isoleucine (ATC) substitution at nucleotide 1023 in exon 3 
of the Npr1 gene-may be associated with an increased risk 
for essential hypertension and myocardial infarction.
34,35 In 
this study, the genotype distributions showed no significant 
differences between glaucoma patients and controls.
Tunny et al
36 reported that no differences in the allelic 
frequencies of the c.454T>C and IVS2+701G>A polymorphisms 
in the Nppa gene were observed in primary open-angle 
glaucoma patients. But they also reported that PCR-SSCP 
analysis of the 5' proximal promoter region of this gene 
revealed mutations in 19% of the POAG patients in the -595 
to -384 bp region. And he suggested that mutations in the 
5' proximal promoter region of the Nppa gene might 
contribute to altered ANP transcription in at least a 
proportion of patients with familial glaucoma.
In cases of NTG, we could not find the association 
between the Nppa and Npr1 genotypes and NTG group. 
Because the genetic component is more important in the 
younger patients than in the older ones, our results in the 
relatively young NTG patients with mean age of 48.8 years 
indicate that other genetic factors might be involved in the Kor J Ophthalmol Vol.21, No.1, 2007
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development of this disease. However, the possibility of the 
association between NTG and other mutations or sequence 
changes in the Nppa and Npr1 gene cannot be excluded. The 
lack of an association between the common polymorphisms 
of the Nppa and Npr1 gene and NTG may suggest that this 
factor does not have a significant role in the pathogenesis of 
the optic neuropathy in NTG.
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